Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

First-to-patent does not predict first- or best-in-class: analysis of approved small molecule vs. biologic drugs.

Roland GE, Xu JJ, Wagner JA.

Clin Pharmacol Ther. 2015 Jan;97(1):19-21. doi: 10.1002/cpt.13. Epub 2014 Nov 25.

PMID:
25670379
2.
3.

Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.

Cohen MA, Huband MD, Yoder SL, Gage JW, Roland GE.

J Antimicrob Chemother. 1998 Jun;41(6):605-14.

PMID:
9687098
4.

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.

Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ.

J Antimicrob Chemother. 1997 Aug;40(2):205-11.

PMID:
9301985
5.

Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.

Renau TE, Gage JW, Dever JA, Roland GE, Joannides ET, Shapiro MA, Sanchez JP, Gracheck SJ, Domagala JM, Jacobs MR, Reynolds RC.

Antimicrob Agents Chemother. 1996 Oct;40(10):2363-8.

6.

In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.

Cohen MA, Yoder SL, Huband MD, Roland GE, Courtney CL.

Antimicrob Agents Chemother. 1995 Sep;39(9):2123-7.

7.

In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models.

Cohen MA, Wold SA, Meservey MA, Gage JW, Heifetz CL, Mailloux GB, Roland GE, Yoder SL.

Diagn Microbiol Infect Dis. 1994 Jan;18(1):41-7.

PMID:
8026156
8.

In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability.

Cohen MA, Joannides ET, Roland GE, Meservey MA, Huband MD, Shapiro MA, Sesnie JC, Heifetz CL.

Diagn Microbiol Infect Dis. 1994 Jan;18(1):31-9.

PMID:
8026155
9.

In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.

Huband MD, Cohen MA, Meservey MA, Roland GE, Yoder SL, Dazer ME, Domagala JM.

Antimicrob Agents Chemother. 1993 Dec;37(12):2563-70.

10.

Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.

Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA.

J Med Chem. 1992 Dec 11;35(25):4745-50.

PMID:
1469702
11.

In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.

Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Heifetz CL.

Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):403-15.

PMID:
1665775
12.

In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391.

Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Heifetz CL.

Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):245-58.

PMID:
1889177
13.

In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.

Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Domagala JM, Heifetz CL.

Antimicrob Agents Chemother. 1991 Jan;35(1):141-6.

Supplemental Content

Loading ...
Support Center